Autophagy as a Potential Therapy for Malignant Glioma


Por: Escamilla-Ramirez, Angel, Castillo-Rodriguez, Rosa A., Zavala-Vega, Sergio, Jimenez-Farfan, Dolores, Anaya-Rubio, Isabel, Briseno, Eduardo, Palencia, Guadalupe, GUEVARA, PATRICIA, Cruz-Salgado, Arturo, Sotelo, Julio, Trejo-Solis, Cristina

Publicada: 1 jul 2020
Resumen:
Glioma is the most frequent and aggressive type of brain neoplasm, being anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), its most malignant forms. The survival rate in patients with these neoplasms is 15 months after diagnosis, despite a diversity of treatments, including surgery, radiation, chemotherapy, and immunotherapy. The resistance of GBM to various therapies is due to a highly mutated genome; these genetic changes induce a de-regulation of several signaling pathways and result in higher cell proliferation rates, angiogenesis, invasion, and a marked resistance to apoptosis; this latter trait is a hallmark of highly invasive tumor cells, such as glioma cells. Due to a defective apoptosis in gliomas, induced autophagic death can be an alternative to remove tumor cells. Paradoxically, however, autophagy in cancer can promote either a cell death or survival. Modulating the autophagic pathway as a death mechanism for cancer cells has prompted the use of both inhibitors and autophagy inducers. The autophagic process, either as a cancer suppressing or inducing mechanism in high-grade gliomas is discussed in this review, along with therapeutic approaches to inhibit or induce autophagy in pre-clinical and clinical studies, aiming to increase the efficiency of conventional treatments to remove glioma neoplastic cells.

Filiaciones:
Escamilla-Ramirez, Angel:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

Castillo-Rodriguez, Rosa A.:
 CONACYT Inst Nacl Pediat, Lab Oncol Expt, Mexico City 04530, DF, Mexico

Zavala-Vega, Sergio:
 Inst Nacl Neurol & Neurocirug, Dept Patol, Mexico City 14269, DF, Mexico

Jimenez-Farfan, Dolores:
 Univ Nacl Autonoma Mexico, Lab Inmunol, Div Estudios Posgrad & Invest, Fac Odontol, Mexico City 04510, DF, Mexico

Anaya-Rubio, Isabel:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

Briseno, Eduardo:
 Inst Nacl Neurol & Neurocirug, Clin Neurooncol, Mexico City 14269, DF, Mexico

Palencia, Guadalupe:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

GUEVARA, PATRICIA:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

Cruz-Salgado, Arturo:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

Sotelo, Julio:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico

Trejo-Solis, Cristina:
 Inst Nacl Neurol & Neurocirug, Dept Neuroinmunol, Mexico City 14269, DF, Mexico
ISSN: 14248247
Editorial
MDPI AG, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Review
Volumen: 13 Número: 7
Páginas: 1-76
WOS Id: 000554274700001
ID de PubMed: 32707662

MÉTRICAS